APD-356 (Arena)

Curr Opin Investig Drugs. 2005 Oct;6(10):1051-6.

Abstract

Arena is developing APD-356, the lead in a series of orally active, small-molecule 5-hydroxytryptamine 2C agonists for the potential treatment of obesity and diabetes. A phase IIb trial was initiated in June 2005, and preliminary results were expected at the end of 2005.

Publication types

  • Review

MeSH terms

  • Animals
  • Appetite Depressants / chemistry
  • Appetite Depressants / therapeutic use*
  • Benzazepines / chemistry
  • Benzazepines / therapeutic use*
  • Clinical Trials as Topic
  • Diabetes Mellitus / drug therapy*
  • Diabetes Mellitus / metabolism
  • Drug Industry
  • Humans
  • Hypoglycemic Agents / chemistry
  • Hypoglycemic Agents / therapeutic use*
  • Obesity / drug therapy*
  • Obesity / metabolism
  • Serotonin 5-HT2 Receptor Agonists*
  • Structure-Activity Relationship
  • Treatment Outcome

Substances

  • Appetite Depressants
  • Benzazepines
  • Hypoglycemic Agents
  • Serotonin 5-HT2 Receptor Agonists
  • lorcaserin